Scholars@Duke
Andrew Joseph Muir

Andrew Joseph Muir

Professor of Medicine
Medicine, Gastroenterology
andrew.muir@duke.edu
Duke Box 3913, Durham, NC 27710
03137B Hosp South, Durham, NC 27710

Featured Works

Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.

Journal article Hepatology · November 2011 Featured Work UNLABELLED: Retreatment with peginterferon alpha and ribavirin (PR) offers a limited chance of sustained virologic response (SVR) in patients who did not achieve SVR with prior PR treatment. This study evaluated the safety and efficacy of telaprevir-based ... Full text Link to item Cite

Hepatitis C treatment among racial and ethnic groups in the IDEAL trial.

Journal article J Viral Hepat · April 2011 Featured Work Previous studies of chronic hepatitis C virus (HCV) treatment have demonstrated variations in response among racial and ethnic groups including poorer efficacy rates among African American and Hispanic patients. The individualized dosing efficacy vs flat d ... Full text Link to item Cite

Rates of surveillance and management of hepatocellular carcinoma in patients evaluated at a liver transplant center.

Journal article Dig Dis Sci · December 2010 Featured Work OBJECTIVES: The treatment of choice for HCC with cirrhosis is liver transplantation (LT). We assessed if patients evaluated for hepatocellular carcinoma are being diagnosed by surveillance, the proportion of patients meeting Milan criteria at diagnosis, an ... Full text Link to item Cite

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection.

Journal article Hepatology · September 2010 Featured Work UNLABELLED: Interferon lambda 1 (IFN-lambda1) is a type III IFN that produces intracellular responses similar to those of IFN-alpha but in fewer cell types because of differences in the receptor distribution pattern, and this could potentially result in an ... Full text Link to item Cite

Telaprevir for previously treated chronic HCV infection.

Journal article N Engl J Med · April 8, 2010 Featured Work BACKGROUND: Patients with genotype 1 hepatitis C virus (HCV) who do not have a sustained response to therapy with peginterferon alfa and ribavirin have a low likelihood of success with retreatment. METHODS: We randomly assigned patients with HCV genotype 1 ... Full text Link to item Cite

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Journal article Nature · September 17, 2009 Featured Work Chronic infection with hepatitis C virus (HCV) affects 170 million people worldwide and is the leading cause of cirrhosis in North America. Although the recommended treatment for chronic infection involves a 48-week course of peginterferon-alpha-2b (PegIFN ... Full text Link to item Cite

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

Journal article N Engl J Med · August 6, 2009 Featured Work BACKGROUND: Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, these regimens have not been adequately compared. METHODS: At 118 sit ... Full text Link to item Cite

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Journal article N Engl J Med · April 30, 2009 Featured Work BACKGROUND: Current therapy for chronic hepatitis C virus (HCV) infection is effective in less than 50% of patients infected with HCV genotype 1. Telaprevir, a protease inhibitor specific to the HCV nonstructural 3/4A serine protease, rapidly reduced HCV R ... Full text Link to item Cite

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.

Journal article J Hepatol · August 2008 Featured Work BACKGROUND/AIMS: This study assessed the safety and antiviral effects of telaprevir (VX-950) in combination with peginterferon alfa-2a and ribavirin. METHODS: Twelve treatment-naïve patients with chronic genotype 1 hepatitis C virus infection received tela ... Full text Link to item Cite

In the clinic. Hepatitis C.

Journal article Ann Intern Med · June 3, 2008 Featured Work Chronic hepatitis C virus (HCV) infection is the most common blood-borne infection in the United States, with an estimated overall prevalence of 3.2 million persons (1.3%) and prevalence peaks between age 40 to 49 years (1). The worldwide prevalence of HCV ... Full text Link to item Cite

Frequency and predictors of de novo hepatocellular carcinoma in patients awaiting orthotopic liver transplantation during the model for end-stage liver disease era.

Journal article Liver Transpl · February 2008 Featured Work In the current system of allocation, patients awaiting orthotopic liver transplantation (OLT) remain at risk of developing de novo hepatocellular carcinoma (HCC) and removal from the waiting list. Using the United Network for Organ Sharing database, we cal ... Full text Link to item Cite

Treatment of hepatitis C in special populations.

Journal article Clin Liver Dis · November 2006 Featured Work Hepatitis C virus (HCV) is a major cause of liver disease worldwide and is the most common chronic blood-borne infection in the United States. Experience has shown that the epidemiology and the response to treatment of HCV vary in certain patient groups. D ... Full text Link to item Cite

Diagnosis and treatment of chronic hepatitis C infection.

Journal article BMJ · April 29, 2006 Featured Work Full text Link to item Cite

Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection.

Journal article Transplantation · July 15, 2005 Featured Work BACKGROUND: Chronic hepatitis C virus (HCV) infection is the most common indication for orthotopic liver transplantation (OLT) in the United States. Recent studies from selected centers have suggested that older donor age is associated with worse outcomes ... Full text Link to item Cite

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.

Journal article N Engl J Med · May 27, 2004 Featured Work BACKGROUND: Several small studies have reported a lower response rate to interferon alfa among black patients with chronic hepatitis C infection than among white patients. The increased prevalence of infection with hepatitis C virus (HCV) genotype 1, which ... Full text Link to item Cite